Oculis Holding AG announced positive phase 2 ACUITY trial results investigating Privosegtor (OCS-05) in acute optic neuritis at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2025 Congress.

The positive topline results from ACUITY showed Privosegtor’s neuroprotective benefits, including anatomical preservation of the retina and improvements in visual function of 18 ETDRS letters at 3 months in patients suffering from acute optic neuritis, the company said in a press release. The results were consistent with previous animal model studies, in which Privosegtor showed preservation of retinal ganglion cell damage and was associated with improvements in mobility (clinical function disability).

Privosegtor has received orphan drug designation from both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for acute optic neuritis. In addition to this indication, a neuroprotective treatment could potentially have wide applicability in neuro-ophthalmic and neurology indications, the company said.